GlassScriptPhysician profile
Masami Hattori
NPI 1306938055
$4,502.03
in general payments reported to CMS, 2019-2025
35 companies · $43.61 in 2025
The $43.61 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,081 · 2020: $375 · 2021: $614 · 2022: $615 · 2023: $519 · 2024: $254 · 2025: $43.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $605.43 | 2019-2025 | Belbuca |
| Indivior INC. | $556.47 | 2019-2022 | |
| Lilly USA, LLC | $410.64 | 2019-2024 | Emgality, Reyvow |
| Nevro Corp. | $362.81 | 2019-2021 | |
| Abbvie INC. | $291.53 | 2021-2024 | |
| Saluda Medical Americas, INC. | $269.11 | 2022-2023 | Evoke Scs |
| Allergan, INC. | $207.99 | 2019-2021 | |
| Pfizer INC. | $184.03 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $160.66 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $142.32 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.61 | 2019-2020 | |
| Lundbeck LLC | $103.43 | 2021-2023 | Vyepti |
| Mdd US Operations, LLC | $102.71 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $92.02 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $89.89 | 2019 | |
| Amgen INC. | $84.69 | 2019-2021 | |
| Boston Scientific Corporation | $59.36 | 2019 | |
| Tersera Therapeutics LLC | $58.94 | 2019 | |
| Hikma Pharmaceuticals USA | $57.19 | 2021-2022 | |
| Ibsa Pharma INC. | $48.30 | 2021-2022 | |
| West Therapeutics Development, LLC | $41.68 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $39.16 | 2021 | |
| Stryker Corporation | $36.53 | 2019 | |
| Zyla Life Sciences, INC. | $36.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.44 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.78 | 2020 | |
| Kaleo, INC. | $22.65 | 2019 | |
| Assertio Therapeutics, INC. | $22.50 | 2019 | |
| Neuronetics, INC. | $21.85 | 2019 | |
| Globus Medical, INC. | $20.50 | 2025 | Senza |
| Bausch Health US, LLC | $20.31 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.30 | 2019 | |
| Shionogi INC | $13.45 | 2019 | |
| Trevena, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masami Hattori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.